Department of Pathobiological and Medical Diagnostics, Faculty of Medicine and Health Sciences, Universiti Malaysia Sabah, Malaysia.
Department of Pathobiological and Medical Diagnostics, Faculty of Medicine and Health Sciences, Universiti Malaysia Sabah, Malaysia.
J Infect Public Health. 2018 Sep-Oct;11(5):605-610. doi: 10.1016/j.jiph.2018.04.005. Epub 2018 Apr 26.
Rifampicin (RIF) plays a pivotal role in the treatment of tuberculosis due to its bactericidal effects. Because the action of RIF is on rpoB gene encoding RNA polymerase β subunit, 95% of RIF resistant mutations are present in rpoB gene. The majority of the mutations in rpoB gene are found within an 81bp RIF-resistance determining region (RRDR).
Literatures on RIF resistant mutations published between 2010 and 2016 were thoroughly reviewed.
The most commonly mutated codons in RRDR of rpoB gene are 531, 526 and 516. The possibilities of absence of mutation in RRDR of rpoB gene in MDR-TB isolates in few studies was due to existence of other rare rpoB mutations outside RRDR or different mechanism of rifampicin resistance.
Molecular methods which can identify extensive mutations associated with multiple anti-tuberculous drugs are in urgent need so that the research on drug resistant mutations should be extended.
利福平（RIF）由于其杀菌作用在结核病治疗中起着关键作用。由于 RIF 的作用是在编码 RNA 聚合酶β亚基的 rpoB 基因上，因此 95%的 RIF 耐药突变存在于 rpoB 基因中。rpoB 基因中的大多数突变发生在 81bp 的 RIF 耐药决定区（RRDR）内。
彻底回顾了 2010 年至 2016 年期间发表的关于 RIF 耐药突变的文献。
rpoB 基因 RRDR 中最常见的突变密码子是 531、526 和 516。在少数研究中，MDR-TB 分离株的 rpoB 基因 RRDR 中不存在突变的可能性是由于 RRDR 之外存在其他罕见的 rpoB 突变或利福平耐药的不同机制。
迫切需要能够识别与多种抗结核药物相关的广泛突变的分子方法，因此应扩大对耐药突变的研究。
